Nina Kokkonen, Sanna-Kaisa Herukka, Laura Huilaja, Merja Kokki, Anne M. Koivisto, Päivi Hartikainen, Anne M. Remes, Kaisa Tasanen, Increased Levels of the Bullous Pemphigoid BP180 Autoantibody Are Associated with More Severe Dementia in Alzheimer’s Disease, Journal of Investigative Dermatology, Volume 137, Issue 1, 2017, Pages 71-76, ISSN 0022-202X, https://doi.org/10.1016/j.jid.2016.09.010
Increased levels of the bullous pemphigoid BP180 autoantibody are associated with more severe dementia in Alzheimer's disease
|Author:||Kokkonen, Nina1; Herukka, Sanna-Kaisa2; Huilaja, Laura1;|
1Department of Dermatology, PEDEGO Research Unit, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland
2Institute of Clinical Medicine–Neurology, University of Eastern Finland and Department of Neurology, Kuopio University Hospital, Kuopio, Finland
3Department of Anesthesia and Operative Service, Kuopio University Hospital, Kuopio, Finland
|Online Access:||PDF Full Text (PDF, 1 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2019102434617
|Publish Date:|| 2019-10-24
Bullous pemphigoid (BP) is a subepidermal blistering skin disease, which has shown a strong association with neurological diseases in epidemiological studies. The BP autoantigens BP180 and BP230 are expressed in the cutaneous basement membrane and the central nervous system. Using BP180 and BP230 ELISA assays and immunoblotting against BP180, we analyzed the IgG reactivity in the sera of 115 patients with Alzheimer’s disease (AD) and 40 neurologically healthy controls. BP180 autoantibodies were found in 18% of patients with AD, whereas only 3% of controls had positive results (P = 0.019). BP230 values were higher and more often elevated in patients with AD than controls, but not significantly. None of the positive AD sera that recognized the full-length human BP180 in immunoblotting reacted with the cutaneous basement membrane in indirect immunofluorescence analysis. Moreover, a retrospective evaluation of the hospital records of the patients with AD revealed neither BP diagnosis nor BP-like symptoms. Interestingly, increased BP180-NC16A autoantibody values correlated with cognitive decline measured by mini-mental state examination scores, but not with the concentration of AD biomarkers in cerebrospinal fluid. Our findings further the understanding of the role of BP180 as a shared autoantigen in neurodermatological interactions and the association between BP and neurodegenerative diseases.
Journal of investigative dermatology
|Pages:||71 - 76|
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
We thank Anja Mattila and Riitta Vuento for their expert technical assistance. This study was supported by the Academy of Finland grant to NK, Oulu University Hospital to KT, and Kuopio University Hospital to S-KH and AMR.
© 2016 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/.